SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report was filed by BioSig Technologies, Inc. on May 8, 2020, covering events occurring on May 5, 2020, and May 7, 2020. The registrant is a Delaware corporation with principal executive offices in Westport, Connecticut, and its common stock trades on the NASDAQ Capital Market under the symbol BSGM.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and does not contain financial statements or performance metrics.
Material Changes
The report discloses the following material changes regarding the board of directors of ViralClear Pharmaceuticals, Inc., a majority-owned subsidiary of the Company:
- On May 5, 2020, Dennis Purcell was appointed to the board of directors of ViralClear.
- On May 7, 2020, Michael Schmertzler was appointed to the board of directors of ViralClear.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document serves solely to announce the aforementioned board appointments via incorporated press releases.
Key Facts for Investor Verification
- Verify the specific qualifications and background of the newly appointed directors, Dennis Purcell and Michael Schmertzler, via the press releases filed as Exhibits 99.1 and 99.2.
- Confirm the current ownership percentage BioSig Technologies holds in ViralClear Pharmaceuticals to assess the impact of these appointments on subsidiary governance.
- Note that this filing contains no financial data; investors should refer to the most recent 10-Q or 10-K for financial performance.